First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor
First Tracks Biotherapeutics’ ANB033 posted stronger Phase 1b celiac efficacy than Teva’s IL-15 inhibitor, with $168 million funding…
Equity Eagle NASDAQ
First Tracks Biotherapeutics, Inc.
TRAX
1 story
$1.2B Market cap · 2026-10-13
Equity Eagle Tickers on this page
Companies the stories above are also about, besides TRAX.
